UCB’s Roch Doliveux joins Innovative Medicines Initiative board
pharmafile | May 19, 2010 | Appointment | Research and Development | UCB, appointment, research and development
UCB’s chief executive Roch Doliveux has joined the governing board of the Innovative Medicines Initiative.
The IMI is a public-private partnership between the European Union and European pharma body EFPIA, of which Doliveux is a board member.
“One of UCB’s strategies is ‘Partnering to increase value and efficiency’. This statement of belief is at the heart of the IMI,” says Roch Doliveux. “As a leading player in European biomedical research, and through our collaboration with the top-quality consortia established within IMI, we are working to improve the efficiency of the industry in bringing safe, efficacious, cost-effective treatments to patients.
“The collaborative programmes within IMI allow the partners to share pre-competitive data that support drug discovery efforts, bringing not just efficiencies, but also societal and socio-economic benefits.”
Doliveux joined UCB in October 2003 as director general of the pharma sector and deputy chairman of the executive committee. He became chief executive and chairman of the executive committee of UCB Group in January 2005.
The goal of the IMI is to improve the environment for biomedical research and development in Europe and to promote innovation through open collaboration. With its unique and innovative funding mechanism, IMI supports research to speed up the development of better and safer medicines for patients.
The European Commission contributes one billion euros to the IMI, an amount matched in-kind by contributions of at least another one billion euros from EFPIA member companies.
EFPIA director general Brian Ager said: “EFPIA welcomes Roch Doliveux’s appointment to the IMI Governing Board. The IMI has already begun to fulfil its potential in reducing the bottlenecks that slow the delivery of innovative medicines to patients. With UCB’s existing strong track record within IMI, and the company’s ongoing commitment to biomedical research, this appointment can only strengthen the future performance of the initiative.”
Related Content
UCB presents positive results for fenfluramine in CDKL5 deficiency disorder
UCB has announced positive results from its phase 3 GEMZ study, showing that fenfluramine can …
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …
